Malignant ophthalmopathy presenting one week after radioiodine treatment of hyperthyroidism.
A 46-year-old woman presented with malignant ophthalmopathy 1 week after a therapeutic dose of radioiodine for treatment of hyperthyroidism. The patient was a smoker and had clinical evidence of mild thyroid-associated ophthalmopathy (TAO) prior to treatment with radioiodine. Anti-thyrotropin (TSH) receptor antibodies and antiflavoprotein antibodies were not detected at the time of presentation with malignant ophthalmopathy. The patient responded rapidly to anti-inflammatory treatment with intravenous methylprednisolone and orbital radiation.
Burmeister
L A
LA
Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania 15261, USA. Burm+@pitt.edu
Beatty
R L
RL
Wall
J R
JR
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005128:Eye Diseases / Q000209:etiology* / Q000532:radiotherapy / Q000628:therapy; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000532:radiotherapy*; D007457:Iodine Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D007457:Iodine Radioisotopes; D011241:Prednisone; D008775:Methylprednisolone